Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126271601 | 12627160 | 1 | I | 20150128 | 20160725 | 20160805 | 20160805 | EXP | JP-ELI_LILLY_AND_COMPANY-JP201607010969 | ELI LILLY AND CO | 65.00 | YR | F | Y | 0.00000 | 20160805 | CN | JP | JP |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126271601 | 12627160 | 1 | PS | ZYPREXA | OLANZAPINE | 1 | Oral | 5 MG, QD | U | 20592 | 5 | MG | QD | ||||||
126271601 | 12627160 | 2 | C | CISPLATIN. | CISPLATIN | 1 | UNK | Y | 0 | ||||||||||
126271601 | 12627160 | 3 | C | CAPECITABINE. | CAPECITABINE | 1 | UNK | Y | 0 |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
126271601 | 12627160 | 1 | Nausea |
126271601 | 12627160 | 2 | Gastric cancer |
126271601 | 12627160 | 3 | Gastric cancer |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
126271601 | 12627160 | OT |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
126271601 | 12627160 | Hyponatraemia | |
126271601 | 12627160 | Off label use |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
126271601 | 12627160 | 1 | 20150128 | 20150131 | 0 | |
126271601 | 12627160 | 2 | 20150128 | 20150128 | 0 | |
126271601 | 12627160 | 3 | 20150128 | 20150211 | 0 |